AI Financial (AIFC) Q2 2024 earnings summary

Executive summary

• Completed acquisition of ALT5 Sigma, Inc., expanding into fintech with blockchain-powered payment solutions and digital asset services; Q2 results reflect only 45 days of fintech operations post-acquisition, from May 15 to June 29, 2024.

• Discontinued recycling segment; results presented as discontinued operations.

• Focus remains on biotech drug development for non-addictive pain relief and fintech growth, with strategic alternatives for the biotech business under evaluation.

• Positive momentum observed in Q3, with management confident in sustaining profitable growth.

Financial highlights

• Net revenue for the 13 weeks ended June 29, 2024 was $2.2 million, up from $0 in the prior year period due to the ALT5 acquisition; fintech revenues reached $2.17 million for the partial quarter.

• Gross profit for the quarter was $1.1 million, representing a 50.6%–51% gross margin.

• Operating loss from continuing operations was $2.9 million for the quarter, compared to $1.1 million loss in the prior year.

• Net income from continuing operations was $0.6 million for the quarter, compared to $0.1 million in the prior year.

• Net income per share was $0.07, compared to $0.02 for continuing operations and $0.01 for discontinued operations in the prior year.

Outlook and guidance

• Plans to raise additional capital to fund biotech clinical trials and fintech expansion.

• Management expects future revenue growth from fintech operations and potential biotech product approvals, with positive momentum into Q3.

• Ongoing focus on expense management and improving profitability.